AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$ATRC

Dahlquist Karl S. sold $458K of ATRC

Dahlquist Karl S. (Chief Legal Officer) sold 9,370 shares of AtriCure, Inc. (ATRC) at $48.89 ($0.46M total) on 2026-08-24.

Original reporting
SEC EDGAR · Dahlquist Karl S.
Published Aug 26, 2026, 10:50 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ATRC
Neutral
medium confidence
Mentioned
$ATRC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRCNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for ATRC.

02

Market read

Insider sale adds a modest data point for traders monitoring ATRC's stock.

03

What to watch

Potential upcoming regulatory or clinical trial news could change the interpretation of the sale.

Relevance 4/10Novelty 6/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ATRCNeutralMedium confidence
Context

Chief Legal Officer sold 9,370 shares for $458,099.30

Expected impact

Minor downward pressure, likely within normal volatility range

Evidence & confidence

The sale amount ($458k) is small relative to market cap; no pattern of repeated sales reported.

Market effects

Sector

No immediate sector impact; insider activity is company‑specific.

Regional

Limited to U.S. investors tracking ATRC.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a routine diversification rather than a negative signal.

Key entities

  • Company
    AtriCure, Inc.

    Medical device manufacturer listed on NYSE under ticker ATRC.

  • Individual
    Karl S. Dahlquist

    Chief Legal Officer of AtriCure, reporting the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATRC insider trading history →

Related articles

AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
JUL 23
$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi

SEC EDGAR 8-K3 min